Alector (ALEC) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alector (ALEC) has outperformed Sionna Therapeutics (SION) over the past year, losing 37.5% versus a loss of 83.2%. Alector is the larger company by market cap ($219.1 million vs $214.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | SION |
|---|---|---|
| Share price | $1.96 | $4.76 |
| Market cap | $219.07M | $214.92M |
| 1-day change | +2.19% | -1.25% |
| YTD return | +23.08% | -88.28% |
| 1-year return | -37.46% | -83.15% |
| 5-year return | -91.76% | — |
| EPS (TTM) | $-1.09 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $54.97 |
| 52-week low | $1.09 | $4.01 |
| Distance from 52-week high | -42.29% | -91.34% |
| Analyst consensus | hold | hold |
| Avg. price target upside | +68.20% | +341.18% |
| Average volume | 2.77M | 2.19M |
| Shares outstanding | 111.66M | 45.15M |
| Employees | 103 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALEC has outperformed SION by 45.7 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
ALEC vs SION FAQ
Which is bigger, Alector or Sionna Therapeutics?
Alector (ALEC) is larger, with a market capitalization of $219.07M compared with $214.92M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, ALEC or SION?
ALEC returned -37.46% over the past 12 months, compared with -83.15% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Alector and Sionna Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Alector and Biotechnology: Pharmaceutical Preparations for Sionna Therapeutics.